Chat with us, powered by LiveChat

Loading...

Plant-based Biologics Market, by Plant Parts

RA00150

Plant-based Biologics Market, by Plant Parts (Seeds-based, Leaf-based, Tubers-based, Fruits-based, others), by Source (Tobacco, Carrot, Alfalfa, Moss, Rice, Duckweed, Others), Regional Analysis (North America, Europe, Asia Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2019–2026

RA00150

Pages: NA

Mar 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Plant-based Biologics Market

Global Plant-Based Biologics Market Insights 2026:

The global plant-based biologics market forecast will be $164.2 million by 2026, increasing from $102.0 million in 2018 at a healthy CAGR of 6.1%. Europe plant-based biologics market is expected to grow at a healthy CAGR of 8.1% by generating a revenue of $51.5 million, during the forecasted period. Strategic collaborations along with technological advancement sare expected to augment the growth of the Asia-Pacific market.

Plant-based biologicsare also known as plant-made biologics (PMB) and are defined as a Schedule D (biologic) drug manufactured using plant molecular farming. The extensively rising global demand for drugs cannot be met by current production platforms such as mammalian cell culture due to limited scalability and higher cost. Plants provide key benefits such as eukaryotic protein modification and being potentially low in cost and high in scalability. So several plants likecarrot, tobacco, Alfalfa, and many others are highly preferred for the production of biologics. Researchers are mainly focusing on the areassuch as expression vectors, novel vaccine candidates, plant host systems, and glycol-engineering for the advancements of plant-derived biologics.

Rising prevalence of chronic diseases is anticipated to drive the global Plant-based Biologics market

Significantly growing global demand for biologics mainly because of the rise in the cases of chronic diseases such as diabetes, heart disease, Alzheimer's disease, and many others has fueled the global plant-based biologics market in the recent years. The use of plants for the production of biologics removes potential contamination from adventitious agents; this is one of the key factors for the growth of plant-based biologics in the global market.In addition, plant-based biologics offer numerous advantages such as they are low cost along with having the ability to produce novel and complex molecules. Furthermore, many established players are developing plant-derived biologics, by using tobacco, moss, duckweed, alfalfa and other plants. Also, the recent researches in plant-based biologics like plant expression vector development, downstream processing, and glycol-engineering are further projected to boost the growth of global plant-based biologics in the market.

Alternatives such as mammalian-based biologics are anticipated to restrain the global Plant-based Biologics market growth

Substitutes such as mammalian biopharmaceuticals are anticipated to restrain the growth of plant-based biologics market, during the projected period. Also, factors such as allergic reactions to the drugs produced from the genetically engineered plant are further projected to obstruct the growth of plant-based biologics market.

The novel transient expression vectors are projected to create immense opportunities in the global market

The increasing promise of plant-based biologics is highlighted by the many established market players. Recently, the novel transient expression vectors have been developed which are more advanced than traditional plant-derived biologics. These biologics allow the production of highly advanced vaccines and therapeutics to control bioterrorist attacks or potential pandemics. Moreover, these plant-based biologics have features likethey are lower in cost, and they have the ability of high scalability and eukaryotic protein modification. In addition, these plant-made biologics can function as biocontrol agents for food borne pathogens. Thus, these aforementioned factors are anticipated to create lucrative opportunities for the growth of plant-based biologics. 

To know more about Plant-based Biologics Market Drivers, Download Report Sample

https://www.researchdive.com/download-sample/150

Leaf-based biologics have the highest market share and theyare projected to generate a revenue of $71.0million by 2026, rising from $46.0million in 2018. Leaf-based biologics are ideal for making multiple recombinant proteins and antibodies. Leaf-based biologics havea huge number of therapeutic proprieties along with being an important source of phenolic compounds. Moreover, studies prove that the effect of vine leaf extract is significant over cardiovascular diseases (CVDs). These aspects are expected to drive the growth of the leaf-based segment in the global market.

Plant-based Biologics market for duck weed will have significant growth and it is anticipated to account for $12.0 million by 2026, with an increase from $5.0 million in 2018.

Duck weedis considered as simple as well as convenient host for the study of pathogenic bacterial infection. Moreover, duckweed can be used for the comprehensive study of the virulence factors, and the host-pathogen interactions. Also, duckweed is recognized asan essential toolfor the large-scale screening of the discovery of antimicrobial chemicals. Furthermore, duckweeds are small in sizes and have ability to rapid and predominantly undergo vegetative reproduction to form genetically uniform clones. In addition, duckweeds are majorly used as model plants to studygenetics, plant physiology, environmental monitoring, and ecology. Plant-based biologics market for the tobacco sector hasa dominating share in the global market and is further expected to generate a revenueof $71.0 million, by 2026. Tobacco has become the most preferred plant mainly because tobacco grows well indoors and it can be grown in bulk in a small space. Moreover, many leading players such as Mapp Biopharmaceutical - Leaf Bio. are replacing mammalian-based biologics with tobacco-based biologics. A Canadian biotech company, Plant Form, is focusing more to produce monoclonal antibodies and proteins from tobacco to treat Ebola, HIV/AIDS, cancer, and many other disorders.

Regional Insights:

Europe region has a lucrative market and it will reach up to $51.5 million by the end of 2026

Europe regionplant-based biologics market share is anticipated to rise at a CAGR of 8.1% by generating a revenue of $51.5 million by 2026. Growing technological advances, heavy investments in R&D departments, and state-of-the-art innovative technique are some of the driving factors thatare anticipated to boost the demand for plant-based biologics product, and it is further projected to drive the growth of European plant-based biologics market. In addition, companies are focusing more on a strategic partnership to develop manufacturing facilities and plant-based expression technology in countries such as Spain, Czech Republic, and Germany, which is further anticipated to augment the growth of Asian plant-based biologics market.

North America region will have the highest market share, and it is projected to generate a revenue of $87.3 million, during the forecast period.

The plant-based biologics market size in North America generated a revenue of $54.1 million in 2018 and it is anticipated to account for $87.3 million by 2026. 

Leading players of the US are investing heavily in R&D and focusing mainly on the newest technology innovations. For instance, iBio, Inc., has aSystem called FastPharming which combines vertical farming, glycan engineering technologies and automated hydroponics for the production of high-quality vaccines, monoclonal antibodies, and bioinks. Furthermore, these established companies are looking forward to collaboration with other ventures for the large-scale production of antibodies in plants. Furthermore,In Canada, Plant Biosafety Office (PBO) and the Canadian Food Inspection Agency's (CFIA) have started the production of plant-derived biologic drugs.

Some of the significant Plant-based Biologics market players includeIcon Genetics GmbH, Kentucky BioProcessing, Inc., Medicago, Inc., Mapp Biopharmaceautical - Leaf Bio., iBio, PlantForm, Greenovation Biotech GmbH, PhycoBiologics Inc., Ventria Bioscience Inc., and Fraunhofer IME.Plant-based Biologics market players are emphasizing on Merger & acquisition and advanced product developments. These are the frequent strategies followed by the established organizations, for instance, recently, iBio and CC-Pharming Ltd. collaborated to develop products and manufacturing facilities for the Chinese biopharmaceutical market. The first product expected is a biobetter for rituximab. 
 

Porter’s Five Forces Analysis for Plant-based biologics market:

  •   Bargaining Power of Suppliers:Leading suppliers in the healthcare market use negotiating power to gain high prices. Moreover, the switching barrier from one supplier to the other supplier is predicted to be high.
    The bargaining power of suppliers is HIGH.

  •   Bargaining Power of Buyer: healthcare institutions and Hospitals buy plant-derived biologics in larger quantities and impose pressure on pharmaceutical organizations to keep prices in check. 
    The bargaining power of the buyer is MEDIUM.

  •   Threat of New Entrants: Government regulatory policies coupled with higher cost associated with R&D offer low threat of entry from new competitors. 
    The threat of new entrants is LOW.

  •   Threat of Substitutes: The threat of the alternative product is high if it offers a better value proposition that is considerably different from the present service of the industry. 
    The threat of substitutes is LOW.

  •   Competitive Rivalry in the Market: Plant-based biologics market hasa high number of large,small, and medium companies. Market players are mainly following technological advancements, alternative business strategies such as strategic partnerships; this is also a key factor for high competitive rivalry in the global plant-based biologics market.
    The competitive rivalry in the industry is HIGH.  

 

Aspect

Particulars

  Historical Market Estimations

  2018-2019

  Base Year for Market Estimation

  2018

  Forecast timeline for Market Projection

  2019-2026

  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Plant Parts

  • Seeds-based
  • Leaf-based
  • Tubers-based
  • Fruits-based
  • Others

  Segmentation by Source

  • Tobacco
  • Carrot
  • Alfalfa
  • Moss
  • Rice
  • Duckweed
  • Others

  Key Countries Covered

U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, South Korea, Rest of Asia-Pacific, Brazil, Saudi Arabia, United Arab Emirates, Rest of LAMEA

  Key Companies Profiled

  • Icon Genetics GmbH
  • Kentucky BioProcessing, Inc.
  • Medicago, Inc.
  • Mapp Biopharmaceautical - Leaf Bio.
  • iBio
  • PlantForm
  • Greenovation Biotech GmbH
  • PhycoBiologics Inc.
  • Ventria Bioscience Inc.
  • Fraunhofer IME

 

 


FREQUENTLY ASKED QUESTIONS?
 

A. The global Plant-based Biologicsmarketsize was over $102.0 million in 2018 and is projected to reach $164.2million by 2026.

A. Greenovation Biotech GmbH, PhycoBiologics Inc., and Ventria Bioscience Inc.are some of the key players in the global Plant-based Biologics Market.

A. The Europeregion possesses great investment opportunities for the investors to witness the most promising growth in the future.

A. The Europe marketplant-based biologics Marketis anticipated to grow at 8.1% CAGR during the forecast period.

A. Technological advancements, product development, along with joint ventures are the key strategies opted by the operating companies in this market.

A. iBio and Icon Genetics GmbHcompanies are investing more on R&D activities for developing new products and technologies.

1 Research Methodology

1.1 Desk Research
1.2 Real time insights and validation
1.3 Forecast model
1.4 Assumptions and forecast parameters

1.4.1 Assumptions
1.4.2 Forecast parameters

1.5 Data sources

1.5.1 Primary
1.5.2 Secondary

2 Executive Summary

2.1 360° summary
2.2 Plant Parts trends
2.3 Source trends

3 Market overview

3.1 Market segmentation & definitions
3.2 Key takeaways

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 Porter’s five forces analysis

3.3.1 Bargaining power of consumers
3.3.2 Bargaining power of suppliers
3.3.3 Threat of new entrants
3.3.4 Threat of substitutes
3.3.5 Competitive rivalry in the market

3.4 Market dynamics

3.4.1 Drivers
3.4.2 Restraints
3.4.3 Opportunities

3.5 Technology landscape
3.6 Regulatory landscape
3.7 Patent landscape
3.8 Pricing overview

3.8.1 By Plant Parts
3.8.2 By Source

3.9 Market value chain analysis

3.9.1 Stress point analysis
3.9.2 Raw material analysis
3.9.3 Manufacturing process
3.9.4 Distribution channel analysis
3.9.5 Operating vendors

3.9.5.1 Raw material suppliers
3.9.5.2 Product manufacturers
3.9.5.3 Product distributors

3.10 Strategic overview

4 Plant-based Biologics Market, by Plant Parts

4.1 Seeds-based

4.1.1 Market size and forecast, by region, 2018-2026
4.1.2 Comparative market share analysis, 2018 & 2026

4.2 Leaf-based

4.2.1 Market size and forecast, by region, 2018-2026
4.2.2 Comparative market share analysis, 2018 & 2026

4.3 Tubers-based

4.3.1 Market size and forecast, by region, 2018-2026
4.3.2 Comparative market share analysis, 2018 & 2026

4.4 Fruits-based

4.4.1 Market size and forecast, by region, 2018-2026
4.4.2 Comparative market share analysis, 2018 & 2026

4.5 Others

4.5.1 Market size and forecast, by region, 2018-2026
4.5.2 Comparative market share analysis, 2018 & 2026

5 Plant-based Biologics Market, by Source

5.1 Tobacco

5.1.1 Market size and forecast, by region, 2018-2026
5.1.2 Comparative market share analysis, 2018 & 2026

5.2 Carrot

5.2.1 Market size and forecast, by region, 2018-2026
5.2.2 Comparative market share analysis, 2018 & 2026

5.3 Alfalfa

5.3.1 Market size and forecast, by region, 2018-2026
5.3.2 Comparative market share analysis, 2018 & 2026

5.4 Moss

5.4.1 Market size and forecast, by region, 2018-2026
5.4.2 Comparative market share analysis, 2018 & 2026

5.5 Rice

5.5.1 Market size and forecast, by region, 2018-2026
5.5.2 Comparative market share analysis, 2018 & 2026

5.6 Duckweed

5.6.1 Market size and forecast, by region, 2018-2026
5.6.2 Comparative market share analysis, 2018 & 2026

5.7 Others

5.7.1 Market size and forecast, by region, 2018-2026
5.7.2 Comparative market share analysis, 2018 & 2026

6 Plant-based Biologics Market, by region

6.1 North America

6.1.1 Market size and forecast, by plant parts, 2018-2026
6.1.2 Market size and forecast, by source, 2018-2026
6.1.3 Market size and forecast, by country, 2018-2026
6.1.4 Comparative market share analysis, 2018 & 2026

6.1.5 U.S.

6.1.5.1 Market size and forecast, by plant parts, 2018-2026
6.1.5.2 Market size and forecast, by source, 2018-2026
6.1.5.3 Comparative market share analysis, 2018 & 2026

6.1.6 Canada

6.1.6.1 Market size and forecast, by plant parts, 2018-2026
6.1.6.2 Market size and forecast, by source, 2018-2026
6.1.6.3 Comparative market share analysis, 2018 & 2026

6.1.7 Mexico

6.1.7.1 Market size and forecast, by plant parts, 2018-2026
6.1.7.2 Market size and forecast, by source, 2018-2026
6.1.7.3 Comparative market share analysis, 2018 & 2026

6.2 Europe

6.2.1 Market size and forecast, by plant parts, 2018-2026
6.2.2 Market size and forecast, by source, 2018-2026
6.2.3 Market size and forecast, by country, 2018-2026
6.2.4 Comparative market share analysis, 2018 & 2026

6.2.5 Germany 

6.2.5.1 Market size and forecast, by plant parts, 2018-2026
6.2.5.2 Market size and forecast, by source, 2018-2026
6.2.5.3 Comparative market share analysis, 2018 & 2026

6.2.6 UK

6.2.6.1 Market size and forecast, by plant parts, 2018-2026
6.2.6.2 Market size and forecast, by source, 2018-2026
6.2.6.3 Comparative market share analysis, 2018 & 2026

6.2.7 France

6.2.7.1 Market size and forecast, by plant parts, 2018-2026
6.2.7.2 Market size and forecast, by source, 2018-2026
6.2.7.3 Comparative market share analysis, 2018 & 2026

6.2.8 Spain

6.2.8.1 Market size and forecast, by plant parts, 2018-2026
6.2.8.2 Market size and forecast, by source, 2018-2026
6.2.8.3 Comparative market share analysis, 2018 & 2026

6.2.9 Italy 

6.2.9.1 Market size and forecast, by plant parts, 2018-2026
6.2.9.2 Market size and forecast, by source, 2018-2026
6.2.9.3 Comparative market share analysis, 2018 & 2026

6.2.10 Rest of Europe

6.2.10.1 Market size and forecast, by plant parts, 2018-2026
6.2.10.2 Market size and forecast, by source, 2018-2026
6.2.10.3 Comparative market share analysis, 2018 & 2026

6.3 Asia Pacific

6.3.1 Market size and forecast, by plant parts, 2018-2026
6.3.2 Market size and forecast, by source, 2018-2026
6.3.3 Market size and forecast, by country, 2018-2026
6.3.4 Comparative market share analysis, 2018 & 2026

6.3.5 China

6.3.5.1 Market size and forecast, by plant parts, 2018-2026
6.3.5.2 Market size and forecast, by source, 2018-2026
6.3.5.3 Comparative market share analysis, 2018 & 2026

6.3.6 India 

6.3.6.1 Market size and forecast, by plant parts, 2018-2026
6.3.6.2 Market size and forecast, by source, 2018-2026
6.3.6.3 Comparative market share analysis, 2018 & 2026

6.3.7 Australia 

6.3.7.1 Market size and forecast, by plant parts, 2018-2026
6.3.7.2 Market size and forecast, by source, 2018-2026
6.3.7.3 Comparative market share analysis, 2018 & 2026

6.3.8 Rest of Asia Pacific

6.3.8.1 Market size and forecast, by plant parts, 2018-2026
6.3.8.2 Market size and forecast, by source, 2018-2026
6.3.8.3 Comparative market share analysis, 2018 & 2026

6.4 LAMEA

6.4.1 Market size and forecast, by plant parts, 2018-2026
6.4.2 Market size and forecast, by source, 2018-2026
6.4.3 Market size and forecast, by country, 2018-2026
6.4.4 Comparative market share analysis, 2018 & 2026

6.4.5 Latin America 

6.4.5.1 Market size and forecast, by plant parts, 2018-2026
6.4.5.2 Market size and forecast, by source, 2018-2026
6.4.5.3 Comparative market share analysis, 2018 & 2026

6.4.6 Middle East 

6.4.6.1 Market size and forecast, by plant parts, 2018-2026
6.4.6.2 Market size and forecast, by source, 2018-2026
6.4.6.3 Comparative market share analysis, 2018 & 2026

6.4.7 Africa

6.4.7.1 Market size and forecast, by plant parts, 2018-2026
6.4.7.2 Market size and forecast, by source, 2018-2026
6.4.7.3 Comparative market share analysis, 2018 & 2026

7 Company profiles

7.1 Icon Genetics GmbH

7.1.1 Business overview
7.1.2 Financial performance
7.1.3 Product portfolio
7.1.4 Recent strategic moves & developments
7.1.5 SWOT analysis

7.2 Kentucky BioProcessing, Inc.

7.2.1 Business overview
7.2.2 Financial performance
7.2.3 Product portfolio
7.2.4 Recent strategic moves & developments
7.2.5 SWOT analysis

7.3 Medicago, Inc.

7.3.1 Business overview
7.3.2 Financial performance
7.3.3 Product portfolio
7.3.4 Recent strategic moves & developments
7.3.5 SWOT analysis

7.4 MappBiopharmaceautical - Leaf Bio.

7.4.1 Business overview
7.4.2 Financial performance
7.4.3 Product portfolio
7.4.4 Recent strategic moves & developments
7.4.5 SWOT analysis

7.5 iBio

7.5.1 Business overview
7.5.2 Financial performance
7.5.3 Product portfolio
7.5.4 Recent strategic moves & developments
7.5.5 SWOT analysis

7.6 PlantForm

7.6.1 Business overview
7.6.2 Financial performance
7.6.3 Product portfolio
7.6.4 Recent strategic moves & developments
7.6.5 SWOT analysis

7.7 Greenovation Biotech GmbH

7.7.1 Business overview
7.7.2 Financial performance
7.7.3 Product portfolio
7.7.4 Recent strategic moves & developments
7.7.5 SWOT analysis

7.8 PhycoBiologics Inc.

7.8.1 Business overview
7.8.2 Financial performance
7.8.3 Product portfolio
7.8.4 Recent strategic moves & developments
7.8.5 SWOT analysis

7.9 Ventria Bioscience Inc.

7.9.1 Business overview
7.9.2 Financial performance
7.9.3 Product portfolio
7.9.4 Recent strategic moves & developments
7.9.5 SWOT analysis

7.10 Fraunhofer IME

7.10.1 Business overview
7.10.2 Financial performance
7.10.3 Product portfolio
7.10.4 Recent strategic moves & developments
7.10.5 SWOT analysis

 

Plant-Based Biologics Industry to Gain Impetus in the Coming Years

Nowadays, the pharmaceutical sector is extensively under the dominance of protein-based medicines. These medicines are derived by applyingbiotechnological methodson plants,which is scientifically termed as plant-based biologics. The arena of biological manufacturing is currently expanding beyond the boundaries of structurally-complex drugs and is foreseen to embrace spheres.  At present, protein-based biologics is seen as the largest and fastest growing areas of pharmaceutical sector.

What is plant-based biologics?

Plant-based biologics are Schedule D (biologic) drugs that are produced using plant molecular farming.In the past, the use of plant-based cell membranesas an alternativeto mammal cell membranesfor producing biologic medicineshad come to the pole position when a number ofpharmaceutical manufacturers were putting effortsfor inventingan alternative treatmentfor treating Ebola. In 2012, the first plant-bade biologic was approved by the U.S. Food and Drug Administration (USFDA) for treating Gaucher's disease. This medicine was named as ‘taliglucerase alfa’. This approval marked the beginning of a new epoch for plant-based biologics and gave a boost to noveldevelopments in the area of biopharmaceuticals.

Growing demand for plant-based biologics therapies

Today, even though man is climbing the stepstoward modernization, he has failed to upkeep his health and well-being which is giving rise to several life-threating diseases such as diabetes, heart disease, Alzheimer's disease, and many others. Plant-based biologic drugs are extensively used for treating such diseases, and hence the demand for plant-based biologic is currently on rise all over the world. The use of plants for the manufacture of biologic productseliminatespossible contamination from adventitious agents.Furthermore, plant-based biologic drugsare widely preferred over other traditional drugs as they offer several advantages such as low cost, high scalability, and efficiency.All these factors are leading to the increased demand of these drugs from markets all over the world. Additionally, many established companies are now focused onmanufacturing plant-based biologics by using moss, tobacco, duckweed, alfalfa, and other plants. Some of the recent studieson plant-based biologics such as downstream processing, plant expression vector development,and glycol-engineering are seen to fuel the growth of plant-based biologics sector in the upcoming years.

Growing developments in the plant-based biologics sector

As per the Biotechnology Innovation Organization (BIO) 2015, nearly 250 biologic medicines and vaccinations have rehabilitated the lives of millions of patients all across the world. At present, numerous biopharmaceutical manufacturers are focusing onthe developmentof plant-made medicines using different plants. For example, in 2015, LeafBio, Inc., a company focused on pharmaceutical research & development of monoclonal antibody products for the treatment and prevention of viral and infectious diseases was given fast track designation by the U.S. Food and Drug Administration (FDA) for their plant-based medicinenamed ZMapp. This drug was used for the treating Ebola virus disease. At present several other companies are in the plant-based biologics market are undertaking activities such as merges &collaborations, acquisitions, partnerships, and new product launches forobtaining aleading position in the global market. In 2017, Denka, a Japanese company acquired German plant biotech Icon Genetics Inc. for around US$ 85.0 million. This acquisition was done with an intention tosupport Denka forconcentrating on research & development to endure development of innovative biopharmaceuticals. 

Future scope of the plant-based biologics industry

A report by Research Dive says that the plant-based biologics industry  is expected to gain heights by registering a CAGR of 6.1% in the near future.Growing occurrences of chronic diseases all across the globe is foreseen as a major contributor to the growth of global plant-based biologics market. Whereas, the growing developments and increasing investments in the plant-based products is expanding the applications of plant-based biologics in the healthcare industry. Considering all these factors, it is clear that the plant-based market is paving its way toward development and is sure to gain heights in the upcoming future.
 

Purchase Options

Enquire To Buy

Personalize this research

  • Triangulate with your own data
  • Get Data as per your format and defination
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

RELATED TAGS

Plant Based Biologics Biologic

Customers Also Viewed